1. Achieving Long-Term Protection Post-MI

2. Panelists

3. Program Goals

4. Case Study 1

5. Case Study 1 (cont)

6. Case Study 1 (cont)

7. Safe to Stop DAPT?

8. Risk Scores From PARIS

9. Elective Surgery Timing in STEMI Patient With DES

10. Risk of MACE Following Noncardiac Surgery in Patients Post-PCI

11. Leading Risk Factors for MACE Post-Noncardiac Surgery in PCI Patients

12. Platelet Reactivity and Clinical Outcomes at 1-Year Follow-Up: ADAPT-DES

13. DES vs BMS 5 Study Meta-Analysis

14. ZEUS Trial

15. LEADERS FREE

16. Length of DAPT: STEMI Treated With DES US Perspective

17. Post-STEMI Treated With DES: Duration of DAPT European Perspective

18. Case Study 2

19. Case Study 2 (cont)

20. Case Study 2 (cont)

21. Euro Heart Survey: In-Hospital Use of Interventional Strategies for ACS

22. PLATO Cumulative Incidence of Primary Composite of CV Death, MI, and Stroke in Patients Intended for Noninvasive Management

23. TRILOGY ACS

24. CHARISMA

27. Markers of Increased Risk in Our Patient

30. Ischemic Risk and Efficacy of Ticagrelor in Relation to Time From P2Y12 Inhibitor Withdrawal

31. Bleeding Risk Score Patients With ACS

32. THEMIS

33. MATCH Outcomes

34. Calculation of a DAPT Score

35. PPIs

36. Cardiovascular OutcoMes for People Using Anticoagulation StrategieS

37. Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention (TWILIGHT)

38. GLOBAL LEADERS: A Clinical Study Comparing 2 Forms of Antiplatelet Therapy After Stent Implantation

39. Concluding Comments

40. Abbreviations

41. Abbreviations (cont)

42. Abbreviations (cont)